Reuters
20 Jul 2026, 12:44 UTC · 17h ago
Tempus to acquire Personalis for $1.5 billion
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
20 Jul 2026, 12:44 UTC · 17h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Tempus AI is acquiring Personalis for approximately $1.5 billion. — A billion-dollar acquisition indicates significant scaling and consolidation in the precision medicine sector, typically acting as a positive catalyst for the acquirer's long-term growth prospects.
+0.40Tempus AI will integrate Personalis' cancer testing capabilities into its AI-enabled oncology portfolio. — Synergies between AI diagnostics and specialized cancer testing enhance the competitive moat and product offering of the combined entity.
+0.20Which stocks this story touches
Expanding its oncology portfolio through the acquisition of Personalis.
Continue reading
6 related stories
Search tags
Company is being acquired for $1.5 billion, typically providing a premium to shareholders.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
